Growth control and cancer metastasis news

<p>Image: BIST</p>
27 Jun 2018

BIST Director General says modernising research facilities and providing training to boost the social impact of science are the top priorities of the Barcelona Institute of Science and Technology

Barry C. Barish presents theory and technology behind measuring gravitational waves developed at LIGO, for which he won the 2017 Nobel Prize in Physics 

<p>Image: BIST</p>
20 Jun 2018

Barry Barish, 2017 Nobel laureate in Physics, will speak about the ‘new science’ arising from the proof found in 1915 for the gravitational waves Einstein predicted.

The scientific re-evolution based on the new power paradigm, the latest advances in biosensors and in vitro production of specialised cells and human organs are the topics of the three debate panels.

<p>Guiomar Solanas, research associate at the Stem Cells and Cancer Lab</p>
11 May 2018

BIST has selected 12 winners, among them Guiomar Solanas, Jelena Urosevic and Lidia Mateo.

This programme recognises excellence in research and supports women scientists in their transition to leadership positions.

<p>Roger Gomis, head of the Growth Control and Cancer Metastasis Lab</p>
20 Mar 2018

Roger Gomis, head of the Growth Control and Cancer Metastasis Lab at IRB Barcelona, participated in the "Càpsules de ciència” video series produced by TV3. In the video he talks about his work on the biology of the metastatic process—research that may contribute to improving patients' lives.

Link to TV3

<p>Roger Gomis</p>
25 Jan 2018

TV3, La Vanguardia, ABC, El Punt Avui, ARA, Diario Médico, Breast Cancer News, El Mundo, among other national and international media, have published an article about the latest work IRB Barcelona researcher Roger Gomis. In this study the researcher have identified genes involved in the latent asymptomatic stage of breast cancer metastases. This work sheds light on the molecular basis underlying how the expression of certain genes facilitates the spread of metastatic lesions.

Link to TV3

Link to...

<p>Interview on "Tarda Oberta"</p>
25 Jan 2018

Yesterday, Roger Gomis, head of the Growth Control and Cancer Metastasis Lab at IRB Barcelona, participated in a round table on TV3's "Tarda Oberta" to explain the mechanism that allows metastatic cells to leave a latent state.

Link to "Tarda Oberta"

 

<p>Nuclei of metastatic breast cancer cells showing the protein MSK1 in green (Author: Cristina Figueras-Puig, IRB Barcelona)</p>
22 Jan 2018

A team of scientists headed by Roger Gomis at IRB Barcelona reveals one of the mechanisms that allows metastatic cells to leave a latent state.

<p>Dante's View (Death Valley National Park)</p>
14 Nov 2017

The “Innovadores” supplement of El Mundo publishes a report on the "Valley of Death" in biolotechnology. This term refers to the phases that between a scientific discovery and it reaching the market.

The article includes comments by experts Delia Zabra, from the Innovation Department at IRB Barcelona, and ICREA researcher Roger Gomis, founder of the spin-off company Inbiomotion.

<p>Roger Gomis</p>
9 Nov 2017

Virgil Simons from Radio Kanal Barcelona has interviewed ICREA researcher Roger Gomis about breast cancer. Gomis is one of the co-authors of an article recently published in Lancet Oncology in which they identified a group of patients with early breast cancer who could benefit from a preventive treatment of metastasis.

Link to Radio Kanal Barcelona

<p>Roger Gomis, head of the Growth Control and Cancer Metastasis Lab and founder of Inbiomotion, a spin-off of IRB Barcelona and ICREA.</p>
31 Oct 2017

ICREA researcher Roger Gomis, head of the Growth Control and Cancer Metastasis Lab, has recently been awarded a 2016 "Knowledge Industry Grant" (Producte), by the Catalan Government’s Agency for Management of University and Research Grants, for the further development of a therapy for the treatment of breast cancer. His 18-month project, "Lipid targeting in breast cancer", aims to obtain a monoclonal antibody, based on a well-defined molecular target, that is suitable for patient treatment and to complete its pre-clinical development phase.